Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FORUM MARKETS IncATNF · Entity 7020 | Director | September 04, 2023 | September 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FORUM MARKETS Inc
Report date September 04, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,857.019 |
Reported balance
After 2023-09-04 transaction · row 1
1 source rowRow 1 · 2023-09-04 · Grant · Acquired 22,388 · Balance 34,857.019 F1: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.67 · Expires 2033-09-04 | Direct | 15,000 |
Reported balance
After 2023-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-09-04 · Grant · Acquired 15,000 · Balance 15,000 F2: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3. F3: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued in consideration for serving on the Board of Directors and as a Member of the Compensation and Risk, Safety and Regulatory Committees of the Board of Directors, for the quarter ended June 30, 2023. Granted under the registrant's First Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F2: Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's Amended and Restated 2022 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
F3: The options vest at the rate of 1/12th of such options ratably on a monthly basis over the following 12 months on the last day of each calendar month (beginning September 30, 2023), subject to the Reporting Person's continued service to the Company on such vesting dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MARRONE BIO INNOVATIONS INC
Report date July 12, 2022 · Filed July 14, 2022
Section 16 reporting ended · disclosed 2022-07-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-07-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-12 · Grant · Acquired 195,007 · Balance 2,394,141 F1: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement"). F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. Row 2 · 2022-07-12 · Disposition to issuer · Disposed 2,394,141 · Balance 0 F3: Disposed of pursuant to the Merger Agreement in exchange for 210,684 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Florence H. Marrone TOD Pamela G Marrone | 0 |
Reported balance
After 2022-07-12 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-07-12 · Disposition to issuer · Disposed 6,442 · Balance 0 F4: Disposed of pursuant to the Merger Agreement in exchange for 566 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-12 · Exercise / conversion · Disposed 195,007 · Balance 0 F5: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4. F6: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F7: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2026-08-11 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-12 · Disposition to issuer · Disposed 157,500 · Balance 0 F8: This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was cancelled in the Merger in exchange for 3,870 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2029-07-16 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-07-12 · Disposition to issuer · Disposed 500,000 · Balance 0 F9: This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 44,000 Ordinary Shares of BIOX for $16.36 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-05-30 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-07-12 · Disposition to issuer · Disposed 560,000 · Balance 0 F10: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 49,280 Ordinary Shares of BIOX for $18.75 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2023-08-01 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-07-12 · Disposition to issuer · Disposed 1,911 · Balance 0 F11: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.08 · Expires 2023-10-29 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-07-12 · Disposition to issuer · Disposed 63,725 · Balance 0 F11: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share. F12: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.77 · Expires 2023-11-06 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-07-12 · Disposition to issuer · Disposed 482 · Balance 0 F12: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share. F13: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of November 6, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 42 Ordinary Shares of BIOX for $190.57 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2023-09-27 | Direct | 0 |
Reported balance
After 2022-07-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-07-12 · Disposition to issuer · Disposed 84,000 · Balance 0 F14: This option, which provided for vesting over a period of four years with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of September 27, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 7,392 Ordinary Shares of BIOX for $204.66 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
F2: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
F3: Disposed of pursuant to the Merger Agreement in exchange for 210,684 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F4: Disposed of pursuant to the Merger Agreement in exchange for 566 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F5: The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
F6: Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
F7: Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.
F8: This option, which provided for vesting in equal monthly installments over three years, beginning on March 7, 2022, was cancelled in the Merger in exchange for 3,870 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F9: This option, which provided for vesting in equal monthly installments over 48 months at the rate of 1/48th after the vesting commencement date of July 16, 2019, was assumed by BIOX in the Merger and replaced with an option to purchase 44,000 Ordinary Shares of BIOX for $16.36 per share.
F10: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 49,280 Ordinary Shares of BIOX for $18.75 per share.
F11: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of August 1, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 168 Ordinary Shares of BIOX for $136.36 per share.
F12: This option, which provided for vesting with respect to 1/4th of the total shares subject to the option on October 29, 2013, and 1/48th of the total shares subject to the option monthly thereafter for 36 months, was assumed by BIOX in the Merger and replaced with an option to purchase 5,607 Ordinary Shares of BIOX for $137.31 per share.
F13: This option, which provided for vesting over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of November 6, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 42 Ordinary Shares of BIOX for $190.57 per share.
F14: This option, which provided for vesting over a period of four years with 1/4th of the shares subject to the option vesting twelve months after the vesting commencement date of September 27, 2013, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, was assumed by BIOX in the Merger and replaced with an option to purchase 7,392 Ordinary Shares of BIOX for $204.66 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2020 Filed May 5, 2020 17:11 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 40,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-027204 · doc4.xml · derivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,669 Underlying: Common Stock · 40,669 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal installments on each of June 30, 2020, September 30, 2020 and December 31, 2020. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F3 · derivative.expiration_date: The restricted stock units vest in three equal installments on each of June 30, 2020, September 30, 2020 and December 31, 2020. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| May 01, 2020 Filed May 5, 2020 17:11 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 154,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-027204 · doc4.xml · derivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,338 Underlying: Common Stock · 154,338 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units fully vested on the grant date. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units fully vested on the grant date. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:27 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-20-019425 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 20:27 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionCommon Stock | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0001209191-20-019425 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 851,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 18:28 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 22,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-052597 · doc4.xml · derivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,058 Underlying: Common Stock · 22,058 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on October 2, 2019. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on October 2, 2019. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 16:51 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001209191-19-042645 · doc4.xml · derivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-07-16 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, vesting in equal monthly installments over 48 months at the rate of 1/48th after the Vesting Commencement Date of July 16, 2019, subject to Optionee's continued employment. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:33 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionStock Option (Right to buy) · Derivative | 19,092 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-19-023455 · doc4.xml · derivative · entry 6 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,092 Underlying: Common Stock · 19,092 shares Expires 2021-01-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2011. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:33 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionStock Option (Right to buy) · Derivative | 4,779 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-19-023455 · doc4.xml · derivative · entry 5 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,779 Underlying: Common Stock · 4,779 shares Expires 2020-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested with respect to 100% of the total shares subject to the option on the vesting commencement date of January 1, 2011. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:33 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionCommon Stock | 19,092 | $1.19 | $22,769.12 |
DisclosureSEC source: 0001209191-19-023455 · doc4.xml · nonDerivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 841,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:33 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionCommon Stock | 4,779 | $1.19 | $5,699.44 |
DisclosureSEC source: 0001209191-19-023455 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2018 Filed Nov 2, 2018 17:44 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionStock Option (Right to buy) · Derivative | 9,559 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-18-056978 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,559 shares Expires 2019-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of January 1, 2009, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document |
| October 31, 2018 Filed Nov 2, 2018 17:44 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionCommon Stock | 9,559 | $1.19 | $11,400.06 |
DisclosureSEC source: 0001209191-18-056978 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 17:55 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionStock Option (Right to buy) · Derivative | 47,794 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-18-051268 · doc4.xml · derivative · entry 5 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,794 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of November 1, 2008, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 17:55 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Tax withholdingCommon Stock | 34,987 | $2.02 | $70,673.74 |
DisclosureSEC source: 0001209191-18-051268 · doc4.xml · nonDerivative · entry 2 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 808,116 F1 · shares: Represents (i) 28,217 shares withheld to cover the exercise price for the purchase of common stock, and (ii) 6,770 shares withheld to satisfy Company tax withholding obligations. The difference between the number of options exercised (47,794) and the number of shares withheld to pay exercise price and taxes (34,987) results in a net settlement of 12,807 shares. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 17:55 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionCommon Stock | 47,794 | $1.19 | $56,874.86 |
DisclosureSEC source: 0001209191-18-051268 · doc4.xml · nonDerivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 18:53 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantStock Option (Right to Buy) · Derivative | 560,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001209191-18-034855 · doc4.xml · derivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,000 Underlying: Common Stock · 560,000 shares Expires 2028-05-30 F1 · derivative.exercise_date: The shares subject to the option will vest over a period of four years, with 1/4th of the shares subject to the option vesting twelve months after the Vesting Commencement Date of May 3, 2018, and the remaining shares vesting in equal monthly installments over the remaining 36 months at the rate of 1/48th, subject to Optionee's continued employment. Read SEC document |
| March 25, 2018 Filed Mar 26, 2018 19:20 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 40,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021669 · doc4.xml · derivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,704 Underlying: Common Stock · 40,704 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on March 25, 2018. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the total shares subject to the grant on March 25, 2018. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| May 21, 2017 Filed May 23, 2017 17:57 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | GrantRestricted Stock Units · Derivative | 25,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-034718 · doc4.xml · derivative · entry 1 Marrone Pamela G · CIK 0001582885 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,192 Underlying: Common Stock · 25,192 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on the date of the grant. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. F2 · derivative.expiration_date: The restricted stock units vested with respect to 100% of the total shares subject to the grant on the date of the grant. Vested shares will be delivered to the reporting person upon the earlier of the reporting person's separation of service with the Company or immediately prior to a change in control event. Read SEC document |
| September 05, 2014 Filed May 17, 2021 16:39 UTC | MARRONE BIO INNOVATIONS INC MBII · Entity 125354 | Exercise / conversionStock Option (Right to buy) · Derivative | 13,807 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001209191-21-033177 · doc4.xml · derivative · entry 4 Marrone Pamela G · CIK 0001582885 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,807 shares Expires 2021-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested with respect to 25% of the total shares subject to the option on the first anniversary of the vesting commencement date of August 11, 2016, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.